Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medibio (MEB) has signed its first statement of works agreement with Compass Group Plc to begin implementation of its corporate mental health software in the U.K.
  • The software, called Ilumen, gives employers and employees a snapshot of their mental wellbeing to make improvements over time
  • The agreement marks the first stage of the Ilumen roll out to the Compass UK workforce, which allows up to one thousand employees to participate for a minimum period of 12 months
  • Medibio is in the grey, last trading at 0.9 cents

Medibio (MEB) has signed its first statement of works agreement with Compass Group Plc to begin implementation of Ilumen in the U.K.

Ilumen, a corporate mental health software product, gives employers aggregated data to measure and manage the wellbeing of its workforce, while providing the employee with a mental wellbeing “snapshot” to allow them to make improvements over time.  

Employees identified as high-risk will then receive a confidential, personalised notification.

Medibio and Compass Group entered into a global master service agreement in November 2020 to establish a framework for the implementation of Ilumen by Compass’ subsidiaries.

The subsidiaries can implement Ilumen by simply agreeing to a statement of works, which details the number of employees eligible to participate. All other material terms of implementation will be outlines in the master agreement.

The agreement marks the first stage of the Ilumen roll out to the Compass UK workforce, which allows up to one thousand employees to participate for a minimum period of 12 months.

“We are delighted to begin the implementation of Ilumen with Compass UK,” said Medibio SVP of Corporate Health, Jennifer Solitario.

“Compass is a priority, and our discussions with subsidiaries have been progressing nicely, so it is especially rewarding to solidify this arrangement with Compass UK. These companies will act as an excellent reference point as we expand our global outlook for Ilumen.”

Medibio is in the grey, last trading at 0.9 cents at 9:45 am AEDT.

MEB by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.